CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025
CG Oncology, Inc. - Common stock (CGON)
Company Research
Source: GlobeNewswire
IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 8:00 am ET on April 28, 2025, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) to be presented on April 26, 2025, at a Plenary Session at the American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. Individuals can access the webcast via the link on the company's Investor Relations website, https://ir.cgoncology.com. An archive will be available following the completion of the call. About Bladder CancerMore than 85,000 people are estimated to be diagnosed with bladder cancer in 2025. NMIBC is the most common form of bladder cancer, represent
Show less
Read more
Impact Snapshot
Event Time:
CGON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGON alerts
High impacting CG Oncology, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CGON
News
- CG Oncology Undervalued Going Into A Busy 2026 [Seeking Alpha]Seeking Alpha
- SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship AwardGlobeNewswire
- CG Oncology (NASDAQ:CGON) is now covered by analysts at Wedbush. They set an "outperform" rating and a $70.00 price target on the stock.MarketBeat
- How Positive Cretostimogene Trial Updates And Leadership Moves At CG Oncology (CGON) Have Changed Its Investment Story [Yahoo! Finance]Yahoo! Finance
- CG Oncology, Inc. (CGON) is a Buy on Cancer Treatment Development: Truist Securities [Yahoo! Finance]Yahoo! Finance
CGON
Earnings
- 11/14/25 - In-Line
CGON
Sec Filings
- 11/26/25 - Form 4
- 11/26/25 - Form 3
- 11/26/25 - Form 8-K
- CGON's page on the SEC website